Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | HB-302/HB-301 |
Synonyms | |
Therapy Description |
HB-302/HB-301 is a combination of two arenaviruses engineered to express prostatic acid phosphatase (PAP) and prostate specific antigen (PSA), which potentially results in enhanced antitumor activity against PSA- and PAP- expressing prosate cancer cells (NCI Drug Dictionary). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
HB-302/HB-301 | HB-300|HB300|HB 300 | HB-302/HB-301 is a combination of two arenaviruses engineered to express prostatic acid phosphatase (PAP) and prostate specific antigen (PSA), which potentially results in enhanced antitumor activity against PSA- and PAP- expressing prosate cancer cells (NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05553639 | Phase Ib/II | HB-302/HB-301 | HB-302/HB-301 Therapy in Participants With Metastatic Castration-Resistant Prostate Cancer | Terminated | USA | 0 |